For patients exploring tirzepatide for weight management or type 2 diabetes, the clinical case is straightforward — the access pathway is not. Between provider evaluations, insurance formulary rules, prior authorization paperwork, and shifting savings program terms, the gap between “I want to try this medication” and “I have the pen in my hand” can stretch weeks longer than it needs to. This guide walks Hollywood-area patients through that pathway end to end.

Tirzepatide at a Glance

Who Qualifies for Tirzepatide

Practical eligibility comes down to three questions: does your BMI hit the threshold, do you have a qualifying coexisting condition, and are there any contraindications in your medical history? Most patients can answer all three before they ever schedule a visit.

Zepbound (Weight Management) Criteria

You qualify if you meet one of two BMI conditions:

• BMI of 30 or higher. The obesity threshold. For a 5’6″ patient, that lands around 186 lbs; for 5’10”, around 209 lbs. No additional condition required.
• BMI between 27 and 29.9 plus a weight-related condition. Qualifying conditions include hypertension, dyslipidemia, type 2 diabetes or prediabetes, obstructive sleep apnea, non-alcoholic fatty liver disease, or established cardiovascular disease.

Mounjaro (Type 2 Diabetes) Criteria

If you carry a confirmed type 2 diabetes diagnosis, BMI is not a gating factor for Mounjaro — it is approved as an adjunct to diet and exercise for glycemic control in adults and pediatric patients aged 10 and older. Type 1 diabetes is not an approved indication.

When Tirzepatide Is Not Appropriate

Even patients who clear the BMI bar can be ruled out by specific medical history:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Documented severe hypersensitivity to tirzepatide or any excipient
• Active pregnancy or planning pregnancy within two months
• History of severe gastroparesis or other significant GI motility disorder

Getting a Tirzepatide Prescription

Tirzepatide is available only by prescription — there is no over-the-counter pathway. The four-step process below covers what to expect from initial visit to first dose in hand.

Step 1: Choose the Right Prescriber

Any of these providers can write the prescription:

• Primary care physician — fastest entry point if you already have an established relationship
• Endocrinologist — best for patients with complex metabolic profiles
• Obesity medicine specialist — board-certified physicians who manage GLP-1 therapy as their primary focus
• Bariatric or metabolic health clinic — non-surgical programs that bundle medical management with nutrition support
• Telehealth provider — covered separately below

Step 2: Walk In Prepared

Bring or have ready: a current weight and height, your active medication and supplement list, a summary of relevant diagnoses, recent labs (HbA1c, fasting glucose, lipid panel, liver enzymes, TSH), specific goals, and your insurance card.

Step 3: The Clinical Decision

Your provider verifies eligibility, screens for contraindications, reviews the side effect profile and titration schedule, and decides which brand fits your indication. Weight management driver gets a Zepbound prescription. Type 2 diabetes primary — even with weight loss as a meaningful secondary goal — usually gets Mounjaro.

Step 4: Pharmacy Routing and Prior Authorization

The script is sent electronically. Most insurance plans gate tirzepatide behind a prior authorization, which the prescriber’s office submits with clinical documentation. PA turnaround runs anywhere from a few hours on electronic systems to several weeks for cases requiring additional review. Don’t assume silence means denial — call the pharmacy and prescriber’s office to track the file.

The Telehealth Route

Telehealth has become the most common entry point for new GLP-1 prescriptions in Florida. For patients who can’t book an in-person obesity medicine specialist for six weeks — or who prefer not to take a day off work — virtual care closes the gap.

How a Telehealth GLP-1 Visit Works

• Online intake — medical history, weight history, current medications, and goals
• A live video consult with a Florida-licensed physician or nurse practitioner
• If clinically appropriate, the e-prescription is sent to your pharmacy of choice within 24 to 48 hours
• Routine follow-up visits — monthly during titration, then quarterly — to monitor response and dose adjustments

Things to Watch For

• The provider must be licensed in Florida — out-of-state-only platforms cannot legally prescribe to you here
• Insurance billing varies sharply — some platforms are cash-only, some bill in-network, some submit superbills for reimbursement
• Skip any service that issues a prescription based on a quiz alone, with no live clinical contact and no follow-up structure

What Tirzepatide Actually Costs

Cash list price for tirzepatide currently sits between roughly $900 and $1,350 per month, varying by dose strength and pharmacy.

Pharmacy-to-pharmacy variation in the same Hollywood-Hallandale-Aventura corridor can run a hundred dollars or more per fill on identical doses. Worth calling two or three pharmacies before committing.

Insurance Coverage: Where Plans Land

Coverage depends on three variables: the carrier and specific plan design, the indication being prescribed, and the formulary tier the drug sits on. The same patient with the same prescription can pay $50 on one employer plan and $400 on another.

Commercial Plans

Most major commercial carriers — BlueCross plans, UnitedHealthcare, Aetna, Cigna, Humana — list at least one tirzepatide brand on their formulary. Coverage for the diabetes indication (Mounjaro) is consistently broader than coverage for weight management (Zepbound).

Even when a plan lists tirzepatide, expect one or more of these conditions:

• Prior authorization. The default for almost every plan.
• Step therapy. Some plans require failed trials of older agents before authorizing tirzepatide.
• BMI and comorbidity documentation. Specific BMI numbers and named conditions must appear in the chart and on the PA form.
• Tiered cost-sharing. Patient share commonly runs $25 to $250 per month for in-formulary plans.

Marketplace and ACA Plans

Florida’s marketplace plans vary widely on weight management drug coverage. Bronze and Silver tier plans frequently apply higher specialty coinsurance rates that can leave patients paying 30% to 50% of list price even when technically “covered.” Always verify the specific drug under your plan’s formulary lookup tool before assuming coverage exists.

Winning the Prior Authorization

Prior authorization is the single biggest source of friction between patient and pen. It is also the most fixable — the difference between approval and denial is usually documentation quality, not patient eligibility.

What Reviewers Look For

• Current BMI from a recent measured weight (Zepbound) or current HbA1c with a confirmed type 2 diabetes diagnosis (Mounjaro)
• At least one named comorbidity in the chart — explicit ICD-10 coded, not implied
• Note that the patient has been counseled on or attempted lifestyle modification
• No contraindications — specifically, screening for thyroid cancer history and MEN 2
• Prescriber attestation that tirzepatide is being used adjunctively and consistent with FDA labeling

The Submission Loop

• Prescriber’s office submits the PA via electronic portal or fax
• Initial decision typically arrives in 1 to 5 business days; urgent reviews can finish same-day
• If denied, your physician can request a peer-to-peer review — a doctor-to-doctor call that overturns a meaningful share of administrative denials
• If peer-to-peer fails, file a formal appeal; if that fails, request external independent review through the state insurance commissioner’s process

Tactics That Actually Work

• Get the first submission right. Most denials are documentation failures, not eligibility failures.
• Always request peer-to-peer after a denial. Usually the fastest fix and often the most effective.
• Document every comorbidity. A blood pressure reading of 134/86 documented across two visits is hypertension. Sleep study results, lipid labs, A1c values — all belong in the file.
• Use clinics with dedicated PA staff. Practices that handle GLP-1 prescriptions in volume have specialists who navigate these submissions daily.

Manufacturer Savings and Patient Assistance

Eli Lilly — manufacturer of both tirzepatide brands — runs co-pay savings cards and patient assistance programs that meaningfully shift the out-of-pocket math for eligible patients. These layer on top of insurance, not in place of it.

Zepbound Savings Card

Eligible commercially insured patients can use the Zepbound co-pay card to bring monthly out-of-pocket costs down considerably, subject to per-fill and annual program caps. Specific terms shift periodically — check the official Zepbound site or the manufacturer’s savings hotline for current values. Standard eligibility:

• U.S. resident, age 18 or older
• Commercial insurance — savings cards do not apply to Medicare, Medicaid, TRICARE, or VA coverage
• Not enrolled in any state or federal pharmacy assistance program

Mounjaro Savings Card

Mirrors the Zepbound program structure: commercially insured type 2 diabetes patients can register for the card and apply it at participating pharmacies. Confirm current terms on the manufacturer’s site before counting on a specific dollar amount.

Lilly Cares Patient Assistance

For uninsured or underinsured patients meeting income criteria, the Lilly Cares Foundation provides medications at no charge through a documented application process. Income thresholds, paperwork requirements, and renewal cycles apply. Your prescriber’s office or the foundation directly can walk you through the application.

Pharmacy Discount Programs

GoodRx, SingleCare, and similar discount platforms offer modest savings on tirzepatide — usually 5% to 15% off cash list. Discounts cannot be stacked with insurance but can be a useful alternative when coverage is denied. Compare across at least three nearby pharmacies before each fill.

Tirzepatide and Medicare

Medicare coverage depends almost entirely on indication. For diabetes patients, coverage is generally available. For weight-management-only patients, coverage has been historically restricted but is actively expanding.

Mounjaro Under Part D

Mounjaro is widely listed on Medicare Part D formularies as an FDA-approved type 2 diabetes medication. Tier placement, prior authorization gates, and step therapy requirements vary by plan. Run your specific plan through Medicare’s plan finder before assuming coverage and cost-share.

Zepbound Under Part D

Federal statute historically blocked Medicare from covering anti-obesity medications. CMS finalized rules in 2025 that opened the door for Part D plans to cover anti-obesity drugs — including Zepbound — for clinically appropriate beneficiaries beginning in 2026. Implementation is plan-by-plan, and not every Part D contract has updated its formulary yet. Verify your specific plan’s current formulary before assuming Zepbound is covered or excluded.

Why Manufacturer Cards Don’t Help Medicare Patients

Federal anti-kickback statutes prohibit manufacturer co-pay cards from being used by Medicare beneficiaries. If you’re on Medicare and out-of-pocket cost is the barrier, the right path is the Low Income Subsidy (Extra Help) program, state pharmaceutical assistance programs, or the Lilly Cares foundation — which evaluates need based on income rather than insurance type.

No Coverage? Five Real Options

Patients who hit a coverage wall — no plan, plan that excludes weight loss drugs, Medicare without an updated formulary — still have meaningful pathways. Don’t assume a denial letter is the end of the road.

Apply to Lilly Cares

For uninsured patients meeting income guidelines, Lilly Cares can provide medication at no cost. Application requires income documentation and prescriber sign-off.

State Pharmaceutical Assistance

Florida and many other states maintain pharmaceutical assistance programs for residents below specific income thresholds. NeedyMeds.org maintains a current state-by-state directory.

Clinical Trial Participation

Active tirzepatide trials provide medication at no charge to enrolled participants. ClinicalTrials.gov lists current studies and eligibility criteria. Trial commitment includes structured visits and protocol requirements.

Push the Appeal Process

An initial denial is not the final answer. Peer-to-peer review reverses many administrative denials within days. Formal appeals, then external independent review, exist as escalation pathways.

Re-evaluate the Indication

If your plan denies Zepbound but covers Mounjaro, and you carry a clinically valid type 2 diabetes diagnosis, your provider may appropriately prescribe Mounjaro for the diabetes indication. Not a workaround — a legitimate clinical pathway when both indications apply to the same patient.

Frequently Asked Questions

How do I bring up tirzepatide with my doctor?

Be specific. Mention you would like to discuss tirzepatide — Zepbound for weight management or Mounjaro for type 2 diabetes — and reference your current BMI or diabetes status. Most providers in 2026 are familiar with the clinical evidence and prescribing protocols.

How long does the entire process take?

Best case — established provider, in-network insurance, electronic prior authorization, no denial — you can be filling your first prescription within one to two weeks. More commonly, expect three to six weeks total when prior authorization, peer-to-peer review, or pharmacy backorders extend the timeline.

Can I afford tirzepatide without insurance?

Possibly. Cash list price runs $900 to $1,350 per month at retail. Lilly Cares can bring that to zero for income-eligible patients. Pharmacy discount platforms shave 5% to 15% off cash. HSA and FSA dollars apply when available. Clinical trial enrollment is another no-cost path.

Does prior authorization always slow things down?

No. Electronic prior authorization systems used by larger practices can return decisions in hours. Practices with experienced PA staff submit cleaner paperwork, get fewer denials, and resolve the ones that come faster.

Are all pharmacies priced the same?

No. Cash and discount-program prices vary meaningfully between pharmacies, even within the same Hollywood-area zip code. Differences of $100 to $300 per month on identical doses are common. Call two or three pharmacies before each refill.

What do I do if my insurance denies the prescription?

First step: peer-to-peer review. Have your prescriber call the insurance reviewer directly. This single step reverses many denials. If that fails, file a formal appeal in writing. If the appeal fails, request external independent review through Florida’s Office of Insurance Regulation.

The Path Forward Starts With One Conversation

Getting tirzepatide is a sequenced process, not a single transaction. Eligibility evaluation, prescription, prior authorization, savings program enrollment, and pharmacy fulfillment all happen in order — and each step rewards preparation. Patients who understand the pathway in advance compress their timeline by weeks and avoid the most common stumbling points.

The first step is simple: a clinical evaluation with a provider who can confirm your eligibility, write the prescription, and quarterback the prior authorization process on your behalf.